Xcout Intel
Rezera
Rezera Inc., formerly known as NodThera, is advancing oral anti-inflammatory NLRP3 inhibitors, including the Ruvonoflast Phase 3 development program, with headquarters in Boston.
Subscribe to see Rezera’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Rezera at a glance
Rezera is a biotechnology company headquartered in United States. Xcout tracks 12 named people at Rezera, including Geoff McDonough (Chief Executive Officer).
Rezera leadership
- Geoff McDonoughChief Executive Officer
- Chris GuiffreChief Financial Officer
- Jyothis GeorgeChief Medical Officer
- Nick ClarkeChief Development Officer
- Alan P. WattFounder & Chief Scientific Officer
- David HarrisonVP, Medicinal Chemistry
6 more named people on record for Rezera, with roles, board committees and tenure — see the full roster →
Rezera competitors
A few of Rezera's closest competitors — see the full list of competitors and alternatives →
Mysthera Therapeutics AG is a biotechnology company headquartered in Basel, Switzerland, focused on developing first-in-class, oral therapeutics to treat inflammation-driven and related diseases.
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
Bambusa Therapeutics, Inc. is a biotechnology company focused on immunology and inflammation research, maintaining operational presence both in Boston, Massachusetts and Victoria, Australia.
Rinascera Therapeutics, Inc. is a clinical-stage biotechnology company located in Boston, Massachusetts, dedicated to transforming the treatment of rare genetic skin diseases.
Apogee Therapeutics is a biotechnology company focused on the development of therapies for inflammatory and immunology diseases. The company is headquartered in Waltham, Massachusetts.
Get Rezera's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Rezera in Xcout Intel
- 12 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access